Limits...
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.

Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, Troncone C, Fontana A, Ientile V, Gini R, Santoro D, Santarpia M, Genazzani A, Uomo I, Pastorello M, Addario WS, Scondotto S, Cananzi P, Caputi AP, Trifirò G - BioDrugs (2015)

Bottom Line: The prevalence of ESA use increased from 2.9 to 3.4 per 1000 inhabitants in the years 2009-2011 but decreased thereafter (3.0 per 1000 in 2013).Overall, the prevalence of ESA use decreased slightly, while use of biosimilar ESAs, especially in naive patients, increased significantly but to different extents in these four large Italian geographic areas.New strategies are necessary to further improve market penetration of low-cost medicines, such as biosimilars, and also to harmonize effective health policy interventions that aim to reduce pharmaceutical expenses and optimize patient benefit across all regions.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, ylenia.ingrasciotta@unime.it.

ABSTRACT

Purpose: To explore the prescription patterns of erythropoiesis-stimulating agents (ESAs) in four large Italian geographic areas, where different health policy interventions to promote biosimilar use in routine care are undertaken.

Methods: A retrospective drug utilization study was conducted during the years 2009-2013. The data sources were the administrative databases of the Tuscany region and of the Caserta, Palermo, and Treviso Local Health Units (LHUs). The characteristics, prevalence, and switching patterns of different ESAs (biosimilars and reference products), stratified by indication for use, were calculated over time and across centers.

Results: Overall, 49,491 patients were treated with ESAs during the years 2009-2013 in the four centers. Of these, 41,286 patients (83.4 %) were naive users. The prevalence of ESA use increased from 2.9 to 3.4 per 1000 inhabitants in the years 2009-2011 but decreased thereafter (3.0 per 1000 in 2013). Moreover, the proportion of biosimilar users increased overall from 1.8 % in 2010 to 33.6 % in 2013, with larger increase in Treviso (from 0.0 to 45.0 %) and Tuscany (from 0.7 to 37.6 %) than in Caserta (from 7.5 to 22.9 %) and Palermo (from 0.0 to 27.7 %). Switching between different ESAs during the first year of therapy was frequent (17.0 %), much more toward reference products than toward biosimilars.

Conclusion: Overall, the prevalence of ESA use decreased slightly, while use of biosimilar ESAs, especially in naive patients, increased significantly but to different extents in these four large Italian geographic areas. Switching between different ESAs during the first year of treatment was very frequent, which may affect pharmacovigilance monitoring. New strategies are necessary to further improve market penetration of low-cost medicines, such as biosimilars, and also to harmonize effective health policy interventions that aim to reduce pharmaceutical expenses and optimize patient benefit across all regions.

No MeSH data available.


Switching patterns of erythropoiesis-stimulating agents (ESAs) during the first year of treatment after the index date in all of the centers. The size of each node indicates the number of users; the size of each arrow indicates the proportion of users (minimum 4 %) who switched between one product and another; switching was counted only once per patient, and only the first switch after the index date was considered. Globuren users were grouped with Eprex users, and Nespo users were grouped with Aranesp users. Abseamed was not included in this figure because there were no switchers
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4561997&req=5

Fig5: Switching patterns of erythropoiesis-stimulating agents (ESAs) during the first year of treatment after the index date in all of the centers. The size of each node indicates the number of users; the size of each arrow indicates the proportion of users (minimum 4 %) who switched between one product and another; switching was counted only once per patient, and only the first switch after the index date was considered. Globuren users were grouped with Eprex users, and Nespo users were grouped with Aranesp users. Abseamed was not included in this figure because there were no switchers

Mentions: In Fig. 5, the switching patterns across different ESAs during the first year of treatment after the index date are shown. Switching between different ESAs was very frequent (17.0 %). Among switchers, ESA users switched more frequently toward a reference product (84.1 %) than toward a biosimilar (15.9 %). ESA users switched more frequently to Eprex (29.4 % of total switchers), which is the reference product of epoetin alpha. In addition, switches from Binocrit to Eprex occurred in 27.6 % of Binocrit users in Palermo, in 18.9 % of those in Tuscany, in only 6.7 % of those in Treviso, and in none of those in Caserta.Fig. 5


How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.

Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, Troncone C, Fontana A, Ientile V, Gini R, Santoro D, Santarpia M, Genazzani A, Uomo I, Pastorello M, Addario WS, Scondotto S, Cananzi P, Caputi AP, Trifirò G - BioDrugs (2015)

Switching patterns of erythropoiesis-stimulating agents (ESAs) during the first year of treatment after the index date in all of the centers. The size of each node indicates the number of users; the size of each arrow indicates the proportion of users (minimum 4 %) who switched between one product and another; switching was counted only once per patient, and only the first switch after the index date was considered. Globuren users were grouped with Eprex users, and Nespo users were grouped with Aranesp users. Abseamed was not included in this figure because there were no switchers
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4561997&req=5

Fig5: Switching patterns of erythropoiesis-stimulating agents (ESAs) during the first year of treatment after the index date in all of the centers. The size of each node indicates the number of users; the size of each arrow indicates the proportion of users (minimum 4 %) who switched between one product and another; switching was counted only once per patient, and only the first switch after the index date was considered. Globuren users were grouped with Eprex users, and Nespo users were grouped with Aranesp users. Abseamed was not included in this figure because there were no switchers
Mentions: In Fig. 5, the switching patterns across different ESAs during the first year of treatment after the index date are shown. Switching between different ESAs was very frequent (17.0 %). Among switchers, ESA users switched more frequently toward a reference product (84.1 %) than toward a biosimilar (15.9 %). ESA users switched more frequently to Eprex (29.4 % of total switchers), which is the reference product of epoetin alpha. In addition, switches from Binocrit to Eprex occurred in 27.6 % of Binocrit users in Palermo, in 18.9 % of those in Tuscany, in only 6.7 % of those in Treviso, and in none of those in Caserta.Fig. 5

Bottom Line: The prevalence of ESA use increased from 2.9 to 3.4 per 1000 inhabitants in the years 2009-2011 but decreased thereafter (3.0 per 1000 in 2013).Overall, the prevalence of ESA use decreased slightly, while use of biosimilar ESAs, especially in naive patients, increased significantly but to different extents in these four large Italian geographic areas.New strategies are necessary to further improve market penetration of low-cost medicines, such as biosimilars, and also to harmonize effective health policy interventions that aim to reduce pharmaceutical expenses and optimize patient benefit across all regions.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, ylenia.ingrasciotta@unime.it.

ABSTRACT

Purpose: To explore the prescription patterns of erythropoiesis-stimulating agents (ESAs) in four large Italian geographic areas, where different health policy interventions to promote biosimilar use in routine care are undertaken.

Methods: A retrospective drug utilization study was conducted during the years 2009-2013. The data sources were the administrative databases of the Tuscany region and of the Caserta, Palermo, and Treviso Local Health Units (LHUs). The characteristics, prevalence, and switching patterns of different ESAs (biosimilars and reference products), stratified by indication for use, were calculated over time and across centers.

Results: Overall, 49,491 patients were treated with ESAs during the years 2009-2013 in the four centers. Of these, 41,286 patients (83.4 %) were naive users. The prevalence of ESA use increased from 2.9 to 3.4 per 1000 inhabitants in the years 2009-2011 but decreased thereafter (3.0 per 1000 in 2013). Moreover, the proportion of biosimilar users increased overall from 1.8 % in 2010 to 33.6 % in 2013, with larger increase in Treviso (from 0.0 to 45.0 %) and Tuscany (from 0.7 to 37.6 %) than in Caserta (from 7.5 to 22.9 %) and Palermo (from 0.0 to 27.7 %). Switching between different ESAs during the first year of therapy was frequent (17.0 %), much more toward reference products than toward biosimilars.

Conclusion: Overall, the prevalence of ESA use decreased slightly, while use of biosimilar ESAs, especially in naive patients, increased significantly but to different extents in these four large Italian geographic areas. Switching between different ESAs during the first year of treatment was very frequent, which may affect pharmacovigilance monitoring. New strategies are necessary to further improve market penetration of low-cost medicines, such as biosimilars, and also to harmonize effective health policy interventions that aim to reduce pharmaceutical expenses and optimize patient benefit across all regions.

No MeSH data available.